Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
ABVC BioPharma, Inc. (ABVC) had Consolidated Net Income/Loss of $-0.81M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-0.74M |
|
-- |
|
-- |
|
$0.78M |
|
$-0.78M |
|
$-0.03M |
|
$-0.81M |
|
$-0.79M |
|
$-0.81M |
|
$-0.81M |
|
|
Consolidated Net Income/Loss |
$-0.81M |
$-0.79M |
|
$-0.78M |
|
$-0.69M |
|
26.06M |
|
26.06M |
|
$-0.03 |
|
$-0.03 |
|
| Balance Sheet Financials | |
$0.41M |
|
$12.83M |
|
$18.99M |
|
$19.40M |
|
$5.69M |
|
-- |
|
$1.44M |
|
$7.13M |
|
$12.27M |
|
$12.27M |
|
$12.27M |
|
25.49M |
|
| Cash Flow Statement Financials | |
$-1.14M |
|
$-0.05M |
|
$-0.12M |
|
$1.33M |
|
$0.03M |
|
$-1.29M |
|
$1.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.07 |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.14M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.61% |
|
-6.61% |
|
-4.18% |
|
-6.61% |
|
$0.48 |
|
$-0.04 |
|
$-0.04 |
|